RE:RE:Dr McFarland discussing tlt and our drug Jaro,
Essentially it was very science based discussion on TLD 1433 and other PDCs Theralase owns for other cancer variants.
She said rather doing one pdc for all cancers, they formalize a pdc to specific cancer types. More personalized medicine approach.
It seems she still working in close partnership with Theralase and their relationship still ongoing contrary to what we may have heard on this board in prior months.
She clearly stated if phase 2 data is good, we commercialize this treatment. No phase 3 (huge development for our share price once it materializes). She is working on other cancers as we speak. She mentioned (for competition) there is only one PDC authorized for use in cancer treatment.....forgot the name- starts with the letter "P" I think. This bodes well for us when the FDA reviews for safety and efficacy.
She continues to work and research with follow scientists including some connected to Theralase.
Again, a great deal of science talk which I didn't understand but our drug(s) sound very promising based on her words! She gave a background into discovering the drug and her other company including oral hygiene.
After seeing her on the webcast talking up our drug to many and discussing the Therlase partnership.....I'm very optimistic for the potential future value and successful completion of ph2 trial. Great deal of promise with TLT.